Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$1.41 - $2.31 $1,838 - $3,012
1,304 Added 101.56%
2,588 $3,000
Q3 2023

Oct 30, 2023

BUY
$1.41 - $2.31 $1,838 - $3,012
1,304 Added 101.56%
2,588 $4,000
Q2 2023

May 21, 2024

SELL
$1.5 - $3.04 $24 - $48
-16 Reduced 1.23%
1,284 $2,000
Q2 2023

Jul 27, 2023

SELL
$1.5 - $3.04 $24 - $48
-16 Reduced 1.23%
1,284 $2,000
Q1 2023

May 21, 2024

BUY
$2.8 - $5.46 $940 - $1,834
336 Added 34.85%
1,300 $3,000
Q1 2023

Apr 27, 2023

BUY
$2.8 - $5.46 $940 - $1,834
336 Added 34.85%
1,300 $4,000
Q4 2022

May 21, 2024

BUY
$2.85 - $5.18 $2,747 - $4,993
964 New
964 $3,000
Q4 2022

Jan 31, 2023

BUY
$2.85 - $5.18 $230 - $419
81 Added 9.17%
964 $3,000
Q3 2022

Oct 21, 2022

BUY
$2.85 - $8.73 $2,516 - $7,708
883 New
883 $3,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.